肿瘤坏死因子相关凋亡诱导配体治疗脑胶质瘤的研究进展-肿瘤防治研究.PDF

168 2014 41 2 Cancer Res Prev Treat,2014,Vol.41, No.2 · · 肿瘤防治研究 年第 卷第 期 doi:10.3971/j.issn.1000-8578.2014.02.019 肿瘤坏死因子相关凋亡诱导配体治疗 脑胶质瘤的研究进展 范存刚，张庆俊 Progress in TRAIL-based Therapy for Glioma FAN Cungang, ZHANG Qingjun Department of Neurosurgery, Peking University People’s Hospital, Beijing 100044, China Corresponding Author:ZHANG Qingjun,E-mail:zhangqjpku@126.com Abstract : Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which can specifically kill tumor cells without damaging normal tissue, has been identifi ed as an ideal gene therapy strategy for glioma. Recent studies revealed that both nanoparticles and stem cells could serve as carriers to improve the delivery effi ciency of TRAIL. In addition, the combination of protease inhibitors, chemotherapy drugs, carbenoxolone sodium, miRNA, PI3-kinase/mTOR inhibitor, and etc, could overcome the glioma resistance to TRAIL and enhance the anti-tumor effect of TRAIL. To sum up, TRAIL shows promising prospects in the treatment of glioma. Key words: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); Glioma; Gene therapy; Stem cells; Nanoparticles tumor necrosis factor-related apoptosis-inducing ligand, ：肿瘤坏死因子相关凋亡诱导配体（ TRAIL ）能够特异性杀伤肿瘤细胞而不损伤正常组织，是脑胶质瘤基因治疗的理想策略。新近发现 以纳米粒子和干细胞作为载体能提高TRAIL 的呈递效率，与蛋白酶抑制剂、化疗药物、甘珀酸钠、 miRNA和PI3-激酶/mTOR抑制剂等联合使用有助于克服胶质瘤对TRAIL的耐药性，增强TRAIL的抗肿 瘤功效。由此可见，TRAIL在脑胶质瘤的治疗中具有较广泛的应用前景。 ：肿瘤坏死因子相关凋亡诱导配体；胶质瘤；基因治疗；干细胞；纳米粒子 R730.264 R739.41 A ： ； ： 0 1 TRAIL 肿 瘤 坏 死 因 子 相 关 凋 亡 诱 导 配 体 （ t u m o r 1.1 TRAIL的特点 necrosis factor-related apoptosis-inducing ligand, TRAIL是一种Ⅱ型跨膜蛋白，为肿瘤坏死因 TRAIL ）能够特异性杀伤肿瘤细胞而不损伤正常 子家族成员之一，其突出优点是能够选择性诱导 组织，是较为理想的脑胶质瘤基因治疗策略。然 肿瘤细胞凋亡但对正常细胞没